Drug Profile
Interferon alpha-n1
Alternative Names: WellferonLatest Information Update: 11 Dec 2017
Price :
$50
*
At a glance
- Originator Glaxo Wellcome SA
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Market Withdrawal Cancer; Chronic myeloid leukaemia; Condylomata acuminata; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Recurrent respiratory papillomatosis
Most Recent Events
- 11 Dec 2017 Withdrawn for Hepatitis C in USA before December 2017 (IM)
- 11 Dec 2017 Withdrawn for Hepatitis C in USA before December 2017(SC)
- 28 Feb 2008 Launched for Hepatitis C in USA (IM)